Drug records
69 of the most prescribed drugs in the US. Each page has the shortage status, what pharmacies pay, what Medicare spends and the FDA recalls. Saved Nov 10, 2026.
5 drugs on this list are on the FDA shortage list as of Nov 10, 2026: furosemide, hydrochlorothiazide, lisdexamfetamine, lorazepam, methylphenidate.
| Drug | FDA shortage list | Medicare Part D, 2024 | Recall records |
|---|---|---|---|
| Adalimumab | — | $5.88 billion | 1 |
| Albuterol | — | $720.4 million | 42 |
| Allopurinol | — | $96.3 million | 7 |
| Alprazolam | — | $77.2 million | 33 |
| Amlodipine | — | $332.3 million | 98 |
| Amoxicillin | — | $29.3 million | 20 |
| Apixaban | — | $20.77 billion | 0 |
| Aripiprazole | — | $1.24 billion | 29 |
| Atorvastatin | — | $784.2 million | 68 |
| Azithromycin | — | $47.3 million | 13 |
| Bupropion | — | $342.5 million | 44 |
| Buspirone | — | $111.2 million | 10 |
| Carvedilol | — | $176.9 million | 25 |
| Cephalexin | — | $57.5 million | 24 |
| Citalopram | — | $51.2 million | 8 |
| Clonazepam | — | $74.5 million | 15 |
| Clopidogrel | — | $160.0 million | 7 |
| Cyclobenzaprine | — | $64.2 million | 8 |
| Dapagliflozin | — | $5.49 billion | 1 |
| Doxycycline | — | $128.1 million | 30 |
| Dulaglutide | — | $5.45 billion | 3 |
| Duloxetine | — | $325.9 million | 63 |
| Empagliflozin | — | $11.44 billion | 8 |
| Escitalopram | — | $158.6 million | 2 |
| Famotidine | — | $179.8 million | 23 |
| Finasteride | — | $96.6 million | 17 |
| Fluoxetine | — | $98.6 million | 11 |
| Furosemide | On shortage list | $146.6 million | 14 |
| Gabapentin | — | $610.9 million | 25 |
| Glipizide | — | $90.8 million | 14 |
| Hydrochlorothiazide | On shortage list | $81.2 million | 128 |
| Hydroxyzine | — | $93.0 million | 24 |
| Insulin glargine | — | $2.73 billion | 3 |
| Insulin lispro | — | $971.4 million | 4 |
| Lamotrigine | — | $221.3 million | 13 |
| Levothyroxine | — | $842.7 million | 188 |
| Lisdexamfetamine | On shortage list | $133.3 million | 11 |
| Lisinopril | — | $258.2 million | 41 |
| Lorazepam | On shortage list | $78.4 million | 21 |
| Losartan | — | $359.5 million | 117 |
| Meloxicam | — | $67.7 million | 9 |
| Metformin | — | $408.6 million | 91 |
| Methylphenidate | On shortage list | $54.9 million | 66 |
| Metoprolol | — | $570.9 million | 43 |
| Montelukast | — | $142.0 million | 14 |
| Omeprazole | — | $370.0 million | 17 |
| Ondansetron | — | $141.8 million | 24 |
| Oxycodone | — | $708.0 million | 25 |
| Pantoprazole | — | $331.5 million | 27 |
| Pravastatin | — | $127.0 million | 17 |
| Prednisone | — | $81.5 million | 11 |
| Quetiapine | — | $208.9 million | 12 |
| Rivaroxaban | — | $6.23 billion | 3 |
| Rosuvastatin | — | $468.5 million | 13 |
| Semaglutide | — | $15.16 billion | 57 |
| Sertraline | — | $161.7 million | 7 |
| Sildenafil | — | $46.3 million | 10 |
| Simvastatin | — | $128.0 million | 41 |
| Sitagliptin | — | $3.81 billion | 2 |
| Spironolactone | — | $81.2 million | 11 |
| Tamsulosin | — | $310.7 million | 5 |
| Tirzepatide | — | $6.34 billion | 28 |
| Topiramate | — | $130.1 million | 11 |
| Tramadol | — | $103.3 million | 12 |
| Trazodone | — | $165.4 million | 9 |
| Valsartan | — | $148.4 million | 138 |
| Venlafaxine | — | $160.0 million | 29 |
| Warfarin | — | $46.9 million | 9 |
| Zolpidem | — | $77.8 million | 10 |
Spending counts single-ingredient products only. Recall records are all those that name the ingredient, including combination products. Neither number is a measure of how safe or how good a drug is: widely used drugs have more of both. Any other drug: run a report.